Advertisement
Screener

AXSOME THERAPEUTICS, INC. (AXSM) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments

3.3 / 5 stars · 34/51 Roast Me

AXSOME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments

AXSOME THERAPEUTICS, INC. (AXSM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments · last filed 2026-08-10

  • AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2026-06-30 was $0.00.
  • AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2026-03-31 was $0.00.
  • AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2025-12-31 was $0.00.
  • AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for the quarter ending 2025-09-30 was $0.00.
  • AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2025 was $0.00.
  • AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2024 was $0.00.
  • AXSOME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend payments for fiscal 2023 was $0.00.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments 12 month
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$0.00
10-Q · filed 2026-08-10
$0.00
derived: sum of 3 quarters · filed 2026-08-10
$0.00
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$0.00
10-Q · filed 2026-05-04
$0.00
derived: sum of 2 quarters · filed 2026-05-04
$0.00
derived: sum of 3 quarters · filed 2026-05-04
$0.00
derived: sum of 4 quarters · filed 2026-05-04
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
$0.00
derived: sum of 2 quarters · filed 2026-02-23
$0.00
derived: sum of 3 quarters · filed 2026-02-23
$0.00
10-K · filed 2026-02-23
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
$0.00
derived: sum of 2 quarters · filed 2025-11-03
$0.00
10-Q · filed 2025-11-03
$0.00
derived: sum of 4 quarters · filed 2025-11-03
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04
$0.00
10-Q · filed 2025-08-04
$0.00
derived: sum of 3 quarters · filed 2025-08-04
$0.00
derived: sum of 4 quarters · filed 2025-08-04
2025-03-31$0.00
10-Q · filed 2025-05-05
$0.00
derived: sum of 2 quarters · filed 2025-05-05
$0.00
derived: sum of 3 quarters · filed 2025-05-05
$0.00
derived: sum of 4 quarters · filed 2025-05-05
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18
$0.00
derived: sum of 2 quarters · filed 2025-02-18
$0.00
derived: sum of 3 quarters · filed 2025-02-18
$0.00
10-K · filed 2025-02-18
2024-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
$0.00
derived: sum of 2 quarters · filed 2024-11-12
$0.00
10-Q · filed 2024-11-12
$0.00
derived: sum of 4 quarters · filed 2024-11-12
2024-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05
$0.00
10-Q · filed 2024-08-05
$0.00
derived: sum of 3 quarters · filed 2024-08-05
$0.00
derived: sum of 4 quarters · filed 2024-08-05
2024-03-31$0.00
10-Q · filed 2024-05-06
$0.00
derived: sum of 2 quarters · filed 2024-05-06
$0.00
derived: sum of 3 quarters · filed 2024-05-06
$0.00
derived: sum of 4 quarters · filed 2024-05-06
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23
$0.00
derived: sum of 2 quarters · filed 2024-02-23
$0.00
derived: sum of 3 quarters · filed 2024-02-23
$0.00
10-K · filed 2024-02-23
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$0.00
derived: sum of 2 quarters · filed 2023-11-06
$0.00
10-Q · filed 2023-11-06
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$0.00
10-Q · filed 2023-08-07
2023-03-31$0.00
10-Q · filed 2023-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41